Marino Patricia, Bertucci François, Gonçalves Anthony, Seror Valérie
Institut Paoli-Calmettes, Marseille, France.
Med Sci (Paris). 2012 Mar;28 Spec No 1:19-23. doi: 10.1051/medsci/2012281s106. Epub 2012 Apr 9.
Recent advances in cancer research have led to the development of very expensive new drugs for cancer treatment: the targeted therapies. However, the introduction of these new therapeutic agents which costs are increasing could threaten the diffusion of these innovations. It is thus necessary to determine whether the use of targeted therapies yields clinical benefits that justify their increasing cost. The development of companion diagnosis tests to target drugs and thus to select those patients most likely to benefit from the treatment may provide a useful means of containing the progress of health care expenditures and improve the cost/benefit ratio. In this paper, we present current estimates of health care expenditures linked to the use of targeted therapies for cancer care. We also discuss some of the issues related to the regulatory decisions (pricing and reimbursement) concerning the test/drug couple.
靶向疗法。然而，这些成本不断增加的新型治疗药物的引入可能会威胁到这些创新成果的推广。因此，有必要确定使用靶向疗法是否能带来临床益处，以证明其不断增加的成本是合理的。开发伴随诊断测试以针对药物，从而选择那些最有可能从治疗中受益的患者，可能是控制医疗保健支出增长并提高成本效益比的一种有用方法。在本文中，我们展示了与使用癌症护理靶向疗法相关的医疗保健支出的当前估计。我们还讨论了一些与针对检测/药物组合的监管决策（定价和报销）相关的问题。
